Overview

Glucocorticoid Inflammation Paradox in Human Skeletal Muscle

Status:
Withdrawn
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
In this project, we propose to investigate the metabolic consequences of glucocorticoid therapy, given orally as a 6 day Medrol Dose pack, on human skeletal muscle as measured by western blotting and PCR and skeletal muscle mitochondrial capacity as measured by High-Resolution Respirometry in healthy individuals. Medrol is an FDA approved drug with many clinical indications.
Phase:
Phase 3
Details
Lead Sponsor:
Texas A&M University
Treatments:
Glucocorticoids
Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate